S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:AKRX - Akorn Stock Price, Forecast & News

$1.17
-0.09 (-7.14 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$1.06
Now: $1.17
$1.21
50-Day Range
$1.17
MA: $1.43
$1.72
52-Week Range
$1.06
Now: $1.17
$5.46
Volume2.38 million shs
Average Volume2.85 million shs
Market Capitalization$147.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:AKRX
CUSIP00972810
CIK3116
Phone847-279-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$694.02 million
Cash Flow$0.30 per share
Book Value$3.54 per share

Profitability

Net Income$-401,910,000.00

Miscellaneous

Employees2,191
Market Cap$147.59 million
Next Earnings DateN/A
OptionableOptionable

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter.


Akorn (NASDAQ:AKRX) Frequently Asked Questions

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings results on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.06. The firm earned $176.24 million during the quarter, compared to analyst estimates of $176.15 million. Akorn had a negative return on equity of 19.95% and a negative net margin of 53.62%. The firm's quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the company posted ($0.06) EPS. View Akorn's Earnings History.

What price target have analysts set for AKRX?

3 Wall Street analysts have issued 1-year price targets for Akorn's shares. Their forecasts range from $4.00 to $8.00. On average, they anticipate Akorn's share price to reach $5.67 in the next year. This suggests a possible upside of 384.3% from the stock's current price. View Analyst Price Targets for Akorn.

What is the consensus analysts' recommendation for Akorn?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn.

Has Akorn been receiving favorable news coverage?

Media coverage about AKRX stock has been trending extremely negative recently, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a news sentiment score of -4.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Akorn.

Are investors shorting Akorn?

Akorn saw a increase in short interest in February. As of February 14th, there was short interest totalling 6,940,000 shares, an increase of 14.3% from the January 30th total of 6,070,000 shares. Based on an average trading volume of 2,760,000 shares, the days-to-cover ratio is currently 2.5 days. Approximately 7.0% of the company's shares are short sold. View Akorn's Current Options Chain.

Who are some of Akorn's key competitors?

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Who are Akorn's key executives?

Akorn's management team includes the folowing people:
  • Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
  • Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
  • Dr. Bruce Kutinsky, Consultant (Age 53)
  • Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)

Who are Akorn's major shareholders?

Akorn's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (8.38%), Canyon Capital Advisors LLC (3.96%), State Street Corp (2.67%), Geode Capital Management LLC (1.51%), Connor Clark & Lunn Investment Management Ltd. (1.03%) and Maverick Capital Ltd. (0.98%). Company insiders that own Akorn stock include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

Which institutional investors are selling Akorn stock?

AKRX stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Spark Investment Management LLC, Assenagon Asset Management S.A., Connor Clark & Lunn Investment Management Ltd., UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Akorn.

Which institutional investors are buying Akorn stock?

AKRX stock was purchased by a variety of institutional investors in the last quarter, including Canyon Capital Advisors LLC, Maverick Capital Ltd., Renaissance Technologies LLC, Marshall Wace LLP, Marshall Wace North America L.P., Geode Capital Management LLC, Oxford Asset Management LLP and Gabelli Funds LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

How do I buy shares of Akorn?

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akorn's stock price today?

One share of AKRX stock can currently be purchased for approximately $1.17.

How big of a company is Akorn?

Akorn has a market capitalization of $147.59 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

What is Akorn's official website?

The official website for Akorn is http://www.akorn.com/.

How can I contact Akorn?

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]


MarketBeat Community Rating for Akorn (NASDAQ AKRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  549 (Vote Outperform)
Underperform Votes:  479 (Vote Underperform)
Total Votes:  1,028
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel